(NASDAQ:EKSO) EKSO BIONICS HOLDINGS, shares are soaring this morning on the FDA news that they are approved to market the Robotic Exoskeleton for use with multiple Sclerosis patients.

Shares are up more than 30% and closing in on 6,500 trades in the morning session. $2.29 a share as of writing this post.

Ekso Bionics Receives FDA Clearance to Market its EksoNR Robotic Exoskeleton for Use with Multiple Sclerosis Patients

First FDA Cleared Exoskeleton for Rehabilitation Use in Patients with Multiple Sclerosis

RICHMOND, Calif., June 13, 2022 (GLOBE NEWSWIRE) — Ekso Bionics Holdings, Inc. (Nasdaq:EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its EksoNR robotic exoskeleton for use with Multiple Sclerosis (MS) patients. EksoNR is the first exoskeleton device to receive FDA clearance for rehabilitation use in patients with MS, an indication which significantly expands the devices use to a broader group of patients.


NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.